Patients with CLE who have specific patient characteristics may have lower treatment response than patients who do not have these characteristics.

More than 50% of patients with systemic lupus erythematosus (SLE) develop lupus nephritis (LN) during the disease, which may ...

Royalty Pharma has signed a deal to pay Biogen $250m to support the development of its late-stage experimental lupus ...

The improvement of disease activities was observed across a wide range of SLE manifestations, including skin lesions, joint, fever, nephritis and permitted tapering of corticosteroid during the period ...

GATHER1 and GATHER2 data indicate that ACP could slow the growth of GA lesions while maintaining a favourable safety profile. Its sustained efficacy was evident for more than a two-year follow-up ...

Background: Umbilical cord blood (UCB)-derived CD4 + CD25 + CD127 low regulatory T cells (Tregs) can decrease albuminuria and anti-dsDNA IgG in systemic lupus erythematosus (SLE). Ruxolitinib, a ...

SLE-associated CNS vasculitis was favored because ... small perforating arteries are most commonly affected and the ischemic lesions are localized in the deep or subcortical white matter and ...

In SLE, alternative anti-CD20 antibodies may be more consistently effective ... 19 These long-term data showed a more consistent major response in lupus erythematosus non-specific lesions and oral ...

Systemic lupus erythematosus (SLE) is a heterogeneous multisystem inflammatory disease with wide variability in clinical manifestations. Natural arising CD4+ regulatory T cells (Tregs) play a critical ...

Hypertrophic LE is a rare subset of chronic cutaneous LE and represents 2% of the total chronic cutaneous lesions of LE. [1,2] Hypertrophic LE is similar to discoid LE but with marked ...

I was having lunch with a few other church and ministry leaders within the charismatic movement when I first heard that International House of Prayer (IHOP) founder Mike Bickle had been credibly ...

Cayman Islands, January 28, 2025 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi ...